去甲氧柔红霉素与硼替佐米治疗血液肿瘤的有效性分析

Effectiveness analysis of idarubicin and bortezomib in the treatment of hematologic malignancies

目的探讨去甲氧柔红霉素与硼替佐米治疗血液肿瘤的有效性.方法选取我院2014年9月至2016年9月收治的77例血液肿瘤患者,随机分为参照组（39例）与研究组（38例）.参照组患者给予硼替佐米治疗,研究组患者应用去甲氧柔红霉素治疗.比较分析两组患者的临床疗效及不良反应发生情况.结果研究组患者的治疗总有效率（92.11%）显著高于参照组（69.23%）（P〈0.05）;研究组患者的骨髓抑制发生率显著低于参照组（P〈0.05）;两组患者其他的不良反应发生率比较,差异不具有统计学意义（P〉0.05）.结论在对血液肿瘤患者进行治疗时应用去甲氧柔红霉素,能够获得较为明显的治疗效果,且具有较好的安全性,值得推广.

Objective To investigate the efficacy of idarubicin and bortezomib in the treatment of hematologic malignancies. Methods A total of 77 cases of patients with hematological malignancies treated in our hospital from September 2014 to September 2016 were selected, and randomly divided into reference group （39 cases） and study group （38 cases）. The reference group was treated with bortezomib and the study group were treated with idarubicin. The clinical efficacy and incidence of adverse reactions were analyzed and compared between the two groups. Results The total effective rate of the study group was 92.11%, which was significantly higher than 69.23% in the reference group （ P〈0.05）; the incidence rate of myelosuppression in the study group was significantly lower than that in the reference group （ P〈0.05）, and there was no statistically significant difference in the incidence of other adverse events between the two groups （P〉0.05）. Conclusion In the treatment of patients with hematologic malignancies, the application of idarubicin can abtain obvious treatment effect, with high safety, which is worthy of promotion.